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a  b  s  t  r  a  c  t
Genital  infection  with  Schistosoma  haematobium  is  prevalent  in  sub-Saharan  Africa.  Epidemiological  stud-
ies have  observed  that  genital  schistosomiasis  is  associated  with an  increased  odd  of HIV infection  among
women.  We  used  mathematical  modeling  to  explore  the  potential  impact  of  mass  preventive  chemother-
apy  against  schistosomiasis  on  HIV transmission  in three  sub-Saharan  Africa  countries:  Angola,  Kenya,
and  Zambia.  We developed  a model  of female  genital  schistosomiasis  (FGS)  and  HIV  transmission  dynam-
ics, ﬁtting  it  to data  of HIV  and  S. haematobium  prevalences  as  well  as  co-infection.  We  simulated  targeted
mass  drug  administration  (MDA)  with  praziquantel  to  school-age  children  and  mass  treatment  of the
entire  community.  We  estimated  that,  in  S. haematobium  high-risk  communities,  targeted  annual  treat-
ment  of  school-age  children  could  reduce  HIV prevalence  by 20%  (95%  CI: 12–31%)  in Angola,  16% (95%
CI:  10–32%)  in  Kenya,  and  6%  (95%  CI: 3–18%)  in Zambia  after  the  ﬁrst 20 years  of  intervention;  and  would
reduce  HIV  incidence  by  15%  (95%  CI: 13–32%)  in  Angola,  22% (95%  CI: 18–42%)  in Kenya,  and  9% (95% CI:
3–22%)  in Zambia.  Extending  the  intervention  to adults  could  reduce  HIV  prevalence  by  an  additional  2.2%
(95%  CI:  0.2–12.0%)  in Angola,  1.8%  (95%  CI:  0.1–5.2%)  in  Kenya,  and  0.3%  (95%  CI: 0.1–2.1%)  in  Zambia;  and
would  reduce  HIV  incidence  by  an  additional  1.8%  (95%  CI: 0.0–14.4%)  in  Angola,  6.1% (95%  CI:  0.5–12.6%)
in  Kenya,  and  0.8%  (95%  CI: 0.0–2.7%)  in  Zambia.  We  showed  that the  exacerbation  of  HIV transmission
due to  FGS  and  the  probability  of developing  FGS  as  a result  of  childhood  infection  with  S.  haematobium,
were  the most  important  factors  in  determining  the  effectiveness  of  praziquantel  MDA  for  reducing  HIV
transmission.  Praziquantel  MDA  may  be an  innovative  measure  for reducing  schistosomiasis  and  HIV
transmission  in sub-Saharan  Africa,  the  effectiveness  of  which  varies  with  HIV  prevalence.
ublis©  2014  The  Authors.  P
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Sub-Saharan Africa has been devastated by the HIV/AIDS pan-
emic (WHO, 2012a), and is simultaneously disproportionately
urdened by parasitic disease such as schistosomiasis (Hotez
nd Fenwick, 2009a). Epidemiological studies have observed that
enital schistosomiasis caused by Schistosoma haematobium is asso-
iated with an three- to fourfold increased odd of having HIV in
ub-Saharan African women (Kjetland et al., 2006a; Kallestrup et al.,
005; Downs et al., 2011).
Female genital schistosomiasis (FGS) impairs barrier function of
he genital epithelium and results in inﬂammatory and ulcerative
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755-4365/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unhed  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
lesions of the cervix and vagina, which may  facilitate HIV viral entry
and binding to immune cells (Kallestrup et al., 2005; Mbabazi et al.,
2011). Given that S. haematobium infection, typically acquired pri-
marily during childhood (Mbabazi et al., 2011; Fulford et al., 1998),
normally precedes HIV infection, the biologic plausibility and sta-
tistical association collectively provide strong evidence that FGS is
a risk factor for HIV infection.
World Health Organization guidelines for the control of schis-
tosomiasis recommend the frequent and periodic use of mass drug
administration with praziquantel (Gabrielli et al., 2011), a low
cost anti-schistosomal therapy agent against schistosomiasis mor-
bidity (Gabrielli et al., 2011; King et al., 2005). However, these
recommendations are only sporadically implemented (Hotez and
Fenwick, 2009a; Gabrielli et al., 2011). Considering that female gen-
ital schistosomiasis may  be a risk factor for HIV infection, mass
drug administration (MDA) with praziquantel could be an innova-
tive measure for HIV/AIDS prevention in sub-Saharan Africa (King
et al., 2005; Lillerud et al., 2010).
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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We  evaluated the potential effectiveness of mass treatment of
chistosomiasis for reducing HIV transmission in S. haematobium
ndemic communities with different levels of HIV prevalence. For
his, we developed a model of the joint dynamics of HIV and FGS.
sing epidemiological data of HIV and S. haematobium prevalences
nd co-infection (Kjetland et al., 2006a; Downs et al., 2011; WHO,
014; Schur et al., 2011; Steinmann et al., 2006), we parameter-
zed our model and evaluated the potential impact of praziquantel
DA on reducing HIV transmission in S. haematobium endemic
ommunities in Angola, Kenya, and Zambia. These results demon-
trate that the advantages of WHO  praziquantel recommendations
xtend beyond the direct beneﬁts of curtailing the schistosomiasis
urden. The indirect impact of mass praziquantel administration in
erms of reducing HIV transmission may  even exceed those related
o schistosomiasis, the extent of which is depending on the preva-
ence of HIV.
ethods
We  extended a previously developed compartmental model
or the joint dynamics of FGS and heterosexual HIV transmission
detailed in the supplement material) (Ndeffo Mbah et al., 2013a).
e parameterized the model using a Bayesian Melding approach
Poole and Raftery, 2000) and epidemiological data of HIV-FGS co-
nfection in sub-Saharan Africa, S. haematobium prevalence, and
IV prevalence in Angola, Kenya, and Zambia, respectively, from
990 to 2009 (Kjetland et al., 2006a; Downs et al., 2011; WHO,
014; Schur et al., 2011; Steinmann et al., 2006). We  focused on S.
aematobium endemic communities, assuming the S. haematobium
revalence is at equilibrium before the onset of praziquantel MDA.
nce praziquantel MDA  is implemented, we assumed that schisto-
omiasis infected individuals who receive treatment will be cured
t a rate 55% (37–90%) (King et al., 2011), but will remain at risk
f reinfection from snails. We  used our joint model of FGS and HIV
oinfection to determine the effect of praziquantel administration
n reducing HIV transmission in communities where S. haemato-
ium is highly prevalent but HIV prevalence varies: 2% in Angola,
% in Kenya, and 13% in Zambia. We  evaluated the effectiveness
f two intervention strategies of praziquantel administration on
educing HIV transmission: treatment of children only (School-age
trategy), and treatment of children and adults (All-age strategy).
e  assumed that praziquantel is effective treatment in reducing
he risk of developing FGS (WHO, 2006; King et al., 2011; Richter
t al., 1996; Touré et al., 2008; Kjetland et al., 2008). For adult
omen with established FGS, we assumed that praziquantel treat-
ent does not alleviate the genital lesions, contact bleeding, or
essel abnormalities which may  exacerbate HIV infection (Kjetland
t al., 2006b, 2012).
We assumed that praziquantel has a S. haematobium curative
ate of 55% (range 37–90%), as is consistent with epidemiological
ata (Touré et al., 2008; Kjetland et al., 2006b; Croce et al., 2010;
rench et al., 2010; Muchiri et al., 1996; King et al., 2000). For
omen who received praziquantel as a child and those without
stablished FGS, we assumed that they have a reduced risk of 50%
range 40–70%) of developing FGS (Kjetland et al., 2008). We  fur-
her assumed that compliance to MDA  was 80% (range 75–90%) for
hildren and 55% (range 50–60%) for adults, also according to clin-
cal data (Touré et al., 2008; Goldman et al., 2007). We  conducted
 time-dependent global sensitivity analysis to identify and mea-
ure the contribution of each model parameter (Table S1) to the
ariability of the outcome measure: number of HIV cases averted.
peciﬁcally, we computed the Partial Rank Correlation Coefﬁcient
PRCC) (Marino et al., 2008), which measures the strength of mono-
onic association between input parameters and outcome measure.
e also calculated the ﬁrst-order sensitivity index of each param-
ter, which is the expected reduction in the variance of an outputemics 7 (2014) 22–27 23
variable that would be obtained if the input parameter were ﬁxed
instead of empirically uncertain (Saltelli et al., 2008).
Results
We used a Bayesian Melding procedure (Poole and Raftery,
2000) to derive a posterior distribution for each epidemiological
parameter (Tables S1 and S2) for which the model gives the best-
estimated trajectory for HIV prevalence (Fig. 1), S. haematobium
prevalence, and the odds ratio of HIV infection with versus with-
out FGS. As we focused on schistosomiasis endemic communities, S.
haematobium prevalence was to be at equilibrium. The 95% credible
intervals of model predictions of S. haematobium prevalence were
34–62% (compared with 42–72% empirically (Schur et al., 2011;
Steinmann et al., 2006)) for children, and 15–35% (compared with
13–49% empirically (Schur et al., 2011; Steinmann et al., 2006)) for
adults. The odds ratio of HIV infection with FGS versus no FGS was
1.2–7.1 (compared with 1.2–7.3 empirically (Kjetland et al., 2006a;
Downs et al., 2011)).
We  simulated annual praziquantel MDA  to children (School-age
strategy)  and the whole community (All-age strategy) in communi-
ties in Angola, Kenya, and Zambia where S. haematobium is highly
prevalent (Fig. 2). Our simulations show after the ﬁrst 10 years of
the intervention, the School-age strategy would reduce HIV preva-
lence by 14% (95% CI: 8–22%) in Angola, 8% (95% CI: 5–16%) in Kenya,
and 4% (95% CI: 2–11%) in Zambia; and would reduce HIV inci-
dence by 8% (95% CI: 7–21%) in Angola, 16% (95% CI: 14–31%) in
Kenya, and 9% (95% CI: 6–19%) in Zambia. Extending treatment to
the entire community would result additionally reduce HIV preva-
lence by 2.0% (95% CI: 0.1–12.0%) in Angola, 0.2% (95% CI: 0.0–4.1%)
in Kenya, and 0.1% (95% CI: 0.0–1.5%) in Zambia. As for HIV inci-
dence, it would be reduced by 2% (95% CI: 0.2–10.2%) in Angola, 4%
(95% CI: 0.3–8.2%) in Kenya, and 0.7% (95% CI: 0.0–2.5%) in Zambia.
Implementing praziquantel MDA  for a further 10 years (20 years
in total), the School-age strategy would reduce HIV prevalence by
20% (95% CI: 12–31%) in Angola, 15% (95% CI: 10–32%) in Kenya,
and 6% (95% CI: 3–18%) in Zambia; and would reduce HIV inci-
dence by 15% (95% CI: 13–32%) in Angola, 22% (95% CI: 18–42%) in
Kenya, and 9% (95% CI: 3–22%) in Zambia. Extending the interven-
tion to adults would reduce HIV prevalence by an additional 2.2%
(95% CI: 0.2–12.0%) in Angola, 1.8% (95% CI: 0.1–5.2%) in Kenya,
and 0.3% (95% CI: 0.1–2.1%) in Zambia; and would reduce HIV inci-
dence by an additional 1.8% (95% CI: 0.0–14.4%) in Angola, 6.1%
(95% CI: 0.5–12.6%) in Kenya, and 0.8% (95% CI: 0.0–2.7%) in Zam-
bia.
Our sensitivity analyses showed that the most inﬂuential
parameters for achieving the praziquantel-mediated reduction of
HIV prevalence were primarily parameters that govern HIV trans-
mission (HIV transmission rate from men  to women, exacerbation
of HIV transmission due to FGS, HIV infectious period, and the
decline rate of HIV transmission) and FGS prevalence (probabil-
ity of developing FGS as a result of childhood infection with S.
haematobium; Figs. 3 and 4).
Discussion
We developed a model of joint HIV and FGS dynamics to evalu-
ate the potential impact of praziquantel MDA  on HIV transmission
in S. haematobium endemic areas. Our analysis shows that the
effectiveness of praziquantel MDA  for reducing HIV infections in
sub-Saharan Africa would vary with the country-level HIV preva-
lence. However, counter-intuitively, the proportional impact on
HIV prevalence may  not be necessarily greatest when HIV preva-
lence is highest. Instead, the phase in the trajectory of the HIV
epidemic is more important to the impact that praziquantel MDA
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Tig. 1. HIV prevalence in Angola, Kenya, and Zambia. HIV prevalence data are sho
enerated from the mode (i.e. best ﬁtting) set of input parameters is shown as a solid
f  the references to color in this ﬁgure legend, the reader is referred to the web  ver
as on reducing HIV transmission. More speciﬁcally, we  show that
nnual mass treatment of school age children in S. haematobium
igh prevalence communities in Angola, Kenya, and Zambia would
educe HIV prevalence by 20% (95% CI: 12–31%), 15% (95% CI:
0–32%), and 6% (95% CI: 3–18%), respectively, after the ﬁrst 20
ears of intervention. Extending the intervention to adults would
educe HIV prevalence by an additional 2.2% (95% CI: 0.2–12.0%) in
ngola, 1.8% (95% CI: 0.1–5.2%) in Kenya, and 0.3% (95% CI: 0.1–2.1%)
ig. 2. Effect of mass drug administration with praziquantel on HIV prevalence and incide
A–C)  Reduction in HIV prevalence and (D–F) reduction in HIV incidence under targeted m
he  error bars represent the 95% conﬁdence intervals. points (error bars represent the 95% conﬁdence intervals). HIV prevalence output
ine (dashed lines are the 2.5th and the 97.5th percentile values). (For interpretation
f this article.)
in Zambia. Our sensitivity analyses showed that the exacerbation
of HIV transmission due to FGS and the probability of develop-
ing FGS as a result of childhood infection with S. haematobium,
were the most important parameters in determining the effec-
tiveness of praziquantel MDA  for reducing HIV transmission. To
evaluate the potential impact of praziquantel MDA  for reducing
HIV transmission in S. haematobium high prevalence communi-
ties in Angola, Kenya, and Zambia, we have coupled national data
nce in S. haematobium high prevalence communities in Angola, Kenya, and Zambia.
ass treatment of school-age children and mass treatment of the entire community.
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dig. 3. Partial rank correlation coefﬁcients (PRCCs) for the most important paramet
n  affecting the effectiveness of mass drug administration with praziquantel for re
RCC  values that were not statistically signiﬁcant (p > 0.05).
n HIV prevalence with local data on schistosomiasis. This may
verestimate the impact of treating schistosomiasis on HIV trans-
ission for S. haematobium-endemic communities where HIV
revalence is lower than national overage and to underestimate
t for communities where HIV prevalence is higher than national
ig. 4. Time-dependent ﬁrst order sensitivity index of the estimated input parameters of
f  reduction of HIV incidence attributable to each input parameter under the school-ag
ynamics.the model under school-age strategy. A parameter was considered to be important
n of HIV prevalence if |PRCC| > 0.4. The area between the dashed lines represents
average. Further study will use community-speciﬁc HIV and schis-
tosomiasis data.
Although the WHO  already recommends mass praziquantel
administration as a policy for the control of schistosomiasis mor-
bidity in sub-Saharan Africa, the policy has been advocated in
 the HIV-schistosomiasis transmission model. The proportion of the total variance
e strategy. We show the sensitivity index of input parameters which impact HIV
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he absence of consideration of its potential impact on HIV trans-
ission. Furthermore, mass praziquantel administration is only
arely and sporadically implemented; with fewer than 15% of indi-
iduals at risk of schistosomiasis receive treatment (Hotez and
enwick, 2009b). Demonstrating the additional indirect beneﬁts
f praziquantel on HIV should help promote the adoption of the
ecommended policies.
Genital schistosomiasis may  interact with other risk factors in
ncreasing the risk of HIV infection. Nevertheless, the biological
lausibility of the causal association between FGS and HIV infection
uggests that FGS prevention may  result in a signiﬁcant reduction
f HIV transmission in S. haematobium high prevalence communi-
ies. Consequently, a prospective randomized controlled study to
est the effect of praziquantel treatment on HIV incidence has been
roposed as a necessary step toward developing a new protocol to
reat schistosomiasis for HIV prevention (Stillwaggon, 2012; WHO,
012b). The model presented here is a ﬁrst step toward predict-
ng the impact of schistosomiasis control on reducing the burden
f HIV in sub-Saharan African countries. Improved clinical and
pidemiological data, especially on FGS acquisition and the effect
f praziquantel MDA  on HIV transmission would facilitate model
arameterization and predictions. Our model does not take into
ccount the fact people’s behavior may  change as a result of mass
arziquantel administration. Such a behavior change may  result
n decreasing exposure to schistosomiasis infected fresh waters.
iven that the prevalence of FGS in adult women is not associated
ith the intensity of infection but rather the presence of infec-
ion (Kjetland et al., 2012), we used a prevalence-based approach
o model the joint HIV schistosomiasis dynamics, rather than an
nfection intensity-based model. In schistosomiasis endemic com-
unities, FGS is generally acquired during childhood but little is
nown about the association between schistosomoasis infection
ntensity and FGS among young women. Epidemiological data on
he association between infection intensity and FGS prevalence
ould be needed to extend our analysis to determine the impact
f infection intensity on the effectiveness of praziquantel MDA  for
educing HIV transmission.
Praziquantel remains the only anthelminthic drug against schis-
osomiasis (King et al., 2000; Hotez and Fenwick, 2009b). Because
f the rapid re-infection generally observed in schistosomiasis-
ndemic areas, periodic praziquantel MDA  has been recom-
ended as the major approach to schistosomiasis control (WHO,
006). Therefore, schistosomiasis control programs would require
idespread and repeated use of praziquantel, which would prob-
bly increase the risk for emergence of praziquantel resistance.
o ensure sustainability of schistosomiasis control and avoid the
stablishment of dependence on mass drug administration, inter-
ention strategies should integrate preventive chemotherapy with
ector control strategies, provision of clean water, development of
dequate sanitation, and community health education for behav-
or change (Utzinger et al., 2009; Spiegel et al., 2010). The effect of
chistosomiasis control on HIV transmission in sub-Saharan Africa
hould also be investigated in the context of increasing antiretro-
iral therapy (ART) coverage. Given that ART may  reduce HIV
ransmission (Cohen et al., 2011; Donnell et al., 2010), an increase
f ART coverage may  have a substantial impact on the effectiveness
f schistosomiasis control for reducing HIV transmission. However,
f people in Africa start ART late in the course of their HIV infec-
ion, the provision of ART is unlikely to reduce overall transmission
igniﬁcantly (Cohen et al., 2011; Garnett et al., 2002).
Praziquantel MDA  is a low cost and cost-effective measure for
reventing the irreversible heavy burden of schistosomiasis in
ub-Saharan Africa (Hotez and Fenwick, 2009b; Fenwick, 2012).
n a previous study, we have shown that praziquantel MDA  may
e a cost-saving measure for reducing HIV transmission in rural
imbabwe (Ndeffo Mbah et al., 2013b). Adding to these compellingemics 7 (2014) 22–27
evidences, the results of our modeling study and that of other clini-
cal and epidemiological studies on the association between FGS and
HIV (Hotez and Fenwick, 2009a; Mbabazi et al., 2011; Kjetland et al.,
2012; Stillwaggon, 2012) provide strong incentive for public health
authorities and international donors to scale-up investments for
schistosomiasis control in sub-Saharan Africa.
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